RecruitingPhase 3NCT06128447
Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Soil Transmitted Helminthiasis (STH)
Studying Ankylostomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zero Point Five Therapeutics
- Intervention
- ZP5-9676 600 mg dose(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 59 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Clínica de Vacinas, Americaninha, Brazil
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06128447 on ClinicalTrials.govOther trials for Ankylostomiasis
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE3NCT06736691Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth InfectionsSwiss Tropical & Public Health Institute
- RECRUITINGPHASE3NCT06282315Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and EffectivenessInsud Pharma
- RECRUITINGPHASE4NCT07145736Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical DiseasesKirby Institute
- RECRUITINGPHASE1NCT01940757Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm LarvaeBaylor College of Medicine